Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.
NCT ID: NCT01636908
Last Updated: 2021-04-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
43 participants
INTERVENTIONAL
2011-08-31
2019-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study
NCT01190241
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)
NCT00750178
Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors
NCT00324480
A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors
NCT04679038
Phase 1 Study With Sorafenib and Sirolimus
NCT00509613
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Kinase inhibitor
Patients are cohort-wise treated with a registered (tyrosine) kinase inhibitor
Sunitinib
50 mg once daily, oral use, 14 days
Sorafenib
400 mg, twice daily, oral use, 14 days
Erlotinib
150 mg once daily, oral use, 14 days
Everolimus
10 mg once daily, oral use, 14 days
Lapatinib
1250 mg once daily, oral use, 14 days
Dasatinib
100 mg once daily, oral use, 14 days
Pazopanib
800 mg once daily, oral use, 14 days
Vemurafenib
960 mg twice daily, oral use, 15-21 days
tumor biopsy
skin biopsy (optional)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sunitinib
50 mg once daily, oral use, 14 days
Sorafenib
400 mg, twice daily, oral use, 14 days
Erlotinib
150 mg once daily, oral use, 14 days
Everolimus
10 mg once daily, oral use, 14 days
Lapatinib
1250 mg once daily, oral use, 14 days
Dasatinib
100 mg once daily, oral use, 14 days
Pazopanib
800 mg once daily, oral use, 14 days
Vemurafenib
960 mg twice daily, oral use, 15-21 days
tumor biopsy
skin biopsy (optional)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* minimum age 18 years
* indication for palliative treatment
* measurable disease with at least one lesion accessable for biopsy
Exclusion Criteria
* recent myocardial infarction or uncontrolled coronary artery disease
* cardiac arrhythmias requiring anti-arrhythmic therapy
* uncontrolled hypertension
* uncontrolled infections
* serious non-healing wound, ulcer or bone fracture
* pregnant or breast feeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amsterdam UMC, location VUmc
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
M. Labots
Medical Oncologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
H.M.W. Verheul, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
VU Medical Center Amsterdam
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VUMedical Center
Amsterdam, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011/128
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.